



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

August 23, 2016

Tepha, Inc.
Ms. Connie H. Garrison
Vice President, Regulatory Affairs
99 Hayden Avenue
Lexington, MA 02421

Re: K161092

Trade/Device Name: GalaSHAPE 3D
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical mesh
Regulatory Class: Class II
Product Code: OOD
Dated: July 21, 2016
Received: July 22, 2016

Dear Ms. Garrison:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

David Krause -S

for Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K161092

Device Name

GalaSHAP 3D

Indications for Use (Describe)

GalaSHAPE™ 3D is indicated for use as a bioresorbable scaffold for soft tissue support and to repair, elevate and reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome. This includes reinforcement of soft tissue in plastic and reconstructive surgery, and general soft tissue reconstruction. GalaSHAPE™ 3D is also indicated for the repair of fascial defects that require the addition of a reinforcing or bridging material to obtain the desired surgical result.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

SUBMITTED BY:

Company Name: Tepha, Inc.
Address: 99 Hayden Avenue Suite 360
 Lexington, MA 02421
Telephone: 781-357-1709
Fax: 781-357-1701

CONTACT PERSON: Connie H. Garrison, MBA, RAC
DATE PREPARED: April 15, 2016
TRADE NAME: GalaSHAPE™ 3D
COMMON and CLASSIFICATION NAME: Mesh, surgical, absorbable, plastic and reconstructive surgery
CLASSIFICATION REG/PANEL: CFR §878.3300 / General and Plastic Surgery
PROCEDURE: OOD

PREDICATE DEVICE:

K140533 GalaFLEX® scaffold

DEVICE DESCRIPTION:

GalaSHAPE 3D is a bioresorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB). P4HB is produced from a naturally occurring monomer and is processed into monofilament fibers and knitted into a surgical scaffold. The scaffold has a slight 3D curvature designed to promote better conformance with a patient's anatomy in locations in which a flat design does not easily conform. P4HB bioresorbs through a process of hydrolysis and hydrolytic enzymatic digestion. It has been developed to optimize resorption rate and prolong strength retention in order to provide support throughout the expected period of healing. Although the scaffold loses strength over time, its porous construction was designed to allow native tissue ingrowth and gradual transfer of load from the scaffold to the tissue.

Pre-clinical implantation studies indicate that the GalaSHAPE 3D retains approximately 70% of its strength at 12 weeks. Bioresorption of the scaffold material will be essentially complete within 18-24 months.

INDICATIONS FOR USE/INTENDED USE:

GalaSHAPE™ 3D is indicated for use as a bioresorbable scaffold for soft tissue support and to repair, elevate and reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome. This includes reinforcement of soft tissue in plastic and reconstructive surgery, and general soft tissue reconstruction. GalaSHAPE™ 3D is also indicated for the repair of fascial defects that require the addition of a

reinforcing or bridging material to obtain the desired surgical result.

The indications for use statement for GalaSHAPE 3D is identical to that of the predicate.

SUMMARY of TECHNOLOGICAL CHARACTERISTICS:

Results from performance testing based on “Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh”, dated March 2, 1999, demonstrate substantial equivalence of GalaSHAPE 3D to the predicate GalaFLEX® scaffold cleared under K140533. The device is unchanged in materials, knit construction, and bioresorption profile from the predicate. Both GalaFLEX scaffold and GalaSHAPE 3D are ethylene oxide sterilized and intended for single use only. Both devices are suitable for soft tissue support, and to repair, elevate, and reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome.

BIOCOMPATIBILITY:

Biocompatibility testing of the predicate device was conducted per the categorization principles in ISO 10993-1:2009. Based on the standard, the device was categorized as an implant device in contact with tissue and bone, and having a duration of contact of greater than 30 days (permanent). Results from the predicate testing coupled with cytotoxicity testing repeated for verification of biocompatibility, support the biocompatibility and safety of the subject device.

ANIMAL STUDIES:

An animal study was conducted to characterize the tissue response, resorption profile, and strength characteristics of the device after implantation. In this study, the subject device and predicate were subcutaneously implanted in rabbits. Necropsies were performed at 4, 8, and 12 week time points. The results from the study support the comparability of GalaSHAPE 3D with the predicate. The local tissue reaction was judged to be similar between the predicate and the shaped mesh, and there was no statistically significant difference ($p > 0.05$) in burst strength between the curved mesh and the GalaFLEX sample groups at each of the time points indicating a comparable bioresorption profile. Comparability of GalaSHAPE 3D and the predicate was also supported by similar molecular weights of the polymer at each of the time points.

CONCLUSION:

Based on the intended use, technological characteristics, biocompatibility studies, and animal testing, GalaSHAPE™ 3D is substantially equivalent to the predicate device.